In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bal Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:BALPHARMA - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	3,243	77	133	304	N/A
6/30/2024	3,432	76	N/A	N/A	N/A
3/31/2024	3,392	74	118	228	N/A
12/31/2023	3,270	35	N/A	N/A	N/A
9/30/2023	3,220	32	N/A	N/A	N/A
6/30/2023	3,048	24	N/A	N/A	N/A
3/31/2023	3,042	26	-162	-15	N/A
12/31/2022	2,958	29	N/A	N/A	N/A
6/30/2022	2,802	43	N/A	N/A	N/A
3/31/2022	2,812	56	183	268	N/A
12/31/2021	2,780	72	N/A	N/A	N/A
6/30/2021	2,692	59	N/A	N/A	N/A
3/31/2021	2,505	47	190	223	N/A
12/31/2020	2,135	-34	N/A	N/A	N/A
9/30/2020	1,936	-73	N/A	N/A	N/A
6/30/2020	1,741	-95	N/A	N/A	N/A
3/31/2020	1,711	-122	182	232	N/A
12/31/2019	1,924	-52	N/A	N/A	N/A
9/30/2019	2,081	-15	N/A	N/A	N/A
6/30/2019	2,206	-21	N/A	N/A	N/A
3/31/2019	2,250	38	-8	78	N/A
12/31/2018	2,264	29	N/A	N/A	N/A
3/31/2018	2,093	28	N/A	6	N/A
12/31/2017	2,111	14	N/A	N/A	N/A
3/31/2017	2,289	18	N/A	63	N/A
12/31/2016	2,210	-3	N/A	N/A	N/A
9/30/2016	2,120	13	N/A	N/A	N/A
6/30/2016	2,016	16	N/A	N/A	N/A
3/31/2016	1,983	14	N/A	-194	N/A
12/31/2015	1,959	47	N/A	N/A	N/A
9/30/2015	1,925	33	N/A	N/A	N/A
6/30/2015	1,861	29	N/A	N/A	N/A
3/31/2015	1,875	36	N/A	145	N/A
12/31/2014	1,846	48	N/A	N/A	N/A
9/30/2014	1,857	54	N/A	N/A	N/A
6/30/2014	1,836	51	N/A	N/A	N/A
3/31/2014	1,789	51	N/A	133	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BALPHARMA's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if BALPHARMA's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if BALPHARMA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BALPHARMA's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if BALPHARMA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BALPHARMA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 01:51
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bal Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Bal Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.65 (vs ₹0.62 in 2Q 2024)

Bal Pharma Limited Approves Dividend

Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet

Upcoming dividend of ₹1.20 per share

Bal Pharma (NSE:BALPHARMA) Is Increasing Its Dividend To ₹1.20

Bal Pharma Limited to Report Q3, 2025 Results on Feb 14, 2025

Bal Pharma Limited's (NSE:BALPHARMA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Investor sentiment improves as stock rises 23%

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Larger Dividend Than Last Year

Dividend increased to ₹1.20

Bal Pharma Limited, Annual General Meeting, Sep 25, 2024

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.06 in 1Q 2024)

Bal Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024

Bal Pharma Limited Announces the Cessation of C. V. Srinivas as Independent Director, Chairman/Member of the Audit Committee, Nomination and Remuneration Committee, Stake Holders Relationship Committee & Corporate Social Responsibility Committees

Investor sentiment improves as stock rises 15%

Insufficient Growth At Bal Pharma Limited (NSE:BALPHARMA) Hampers Share Price

Bal Pharma Limited Recommends Dividend

New minor risk - Share price stability

Full year 2024 earnings released: EPS: ₹4.94 (vs ₹1.64 in FY 2023)

Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?

Third quarter 2024 earnings released: EPS: ₹0.54 (vs ₹0.38 in 3Q 2023)

Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up

New minor risk - Share price stability

Bal Pharma Limited to Report Q3, 2024 Results on Feb 12, 2024

Investor sentiment improves as stock rises 15%

Insufficient new directors

Investor sentiment improves as stock rises 20%

Second quarter 2024 earnings released: EPS: ₹0.62 (vs ₹0.38 in 2Q 2023)

Bal Pharma Limited to Report Q2, 2024 Results on Nov 08, 2023

Bal Pharma Limited Approves Dividend

Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Upcoming dividend of ₹1.00 per share at 1.0% yield

Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

First quarter 2024 earnings released: EPS: ₹0.06 (vs ₹0.19 in 1Q 2023)

Bal Pharma Limited, Annual General Meeting, Sep 25, 2023

Bal Pharma Limited to Report Q1, 2024 Results on Aug 11, 2023

Bal Pharma Limited Appoints Abdul Basith as Company Secretary and Compliance Officer

Bal Pharma Limited Appoints Nicola Neeladri as Additional Director

Bal Pharma Limited Recommends Dividend

Full year 2023 earnings released: EPS: ₹1.67 (vs ₹3.79 in FY 2022)

Bal Pharma Limited to Report Q4, 2023 Results on May 29, 2023

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released

Bal Pharma Limited to Report Q3, 2023 Results on Feb 06, 2023

Bal Pharma Limited Announces Resignation of Mr. G. Rengarajan as Chief Financial Officer

Second quarter 2023 earnings released: EPS: ₹0.07 (vs ₹0.97 in 2Q 2022)

Bal Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

High number of new directors

Bal Pharma Limited Declares Dividend

Upcoming dividend of ₹1.00 per share

Bal Pharma Limited, Annual General Meeting, Sep 19, 2022

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

First quarter 2023 earnings released: EPS: ₹0.19 (vs ₹1.09 in 1Q 2022)

Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00

Bal Pharma Limited to Report Q1, 2023 Results on Aug 11, 2022

Full year 2022 earnings released: EPS: ₹3.79 (vs ₹3.34 in FY 2021)

Bal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent)

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Upcoming dividend of ₹1.00 per share

First quarter 2022 earnings released: EPS ₹1.09 (vs ₹0.30 in 1Q 2021)

Full year 2021 earnings released: EPS ₹3.34 (vs ₹8.62 loss in FY 2020)

Bal Pharma Ltd Announces the Launch of Favipiravir Formulation into Indian Market, Under the Brand Name BALflu

Bal Pharma Limited announced that it expects to receive INR 32.5 million in funding

New 90-day high: ₹60.80

Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?

Third quarter 2021 earnings released: EPS ₹0.22 (vs ₹2.62 loss in 3Q 2020)

Bal Pharma Limited to Report Q3, 2021 Results on Feb 11, 2021

Bal Pharma Limited Appoints Jatish Sheth as Additional Director

Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky

Second quarter 2021 earnings released: EPS ₹0.30

Bal Pharma Limited to Report Q2, 2021 Results on Nov 11, 2020